BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
ZEVALIN (ibritumomab tiuxetan) by Spectrum Dynamics is cd20 antigen (human b-lymphocyte-restricted differentiation antigen, bp35). Approved for non-hodgkin lymphoma, follicular lymphoma. First approved in 2002.
Drug data last refreshed 20h ago
Mechanism of Action
CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). The apparent affinity (K D ) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’s…
Indications (2)
Worked on ZEVALIN at Spectrum Dynamics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.